Related Experiment Video
Updated: Feb 1, 2026

Differentiation and Characterization of Osteoclasts from Human Induced Pluripotent Stem Cells
Published on: March 22, 2024
Diosmetin inhibits osteoclast formation and differentiation and prevents LPS-induced osteolysis in mice
Siyuan Shao1, Fangsheng Fu1, Ziyi Wang2
1Research Centre for Regenerative Medicine, Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Abstract:
Osteolytic bone diseases are closely linked to the over-activation of osteoclasts and enhancement of bone resorption. It has become a major health issue in orthopedic practice worldwide. Inhibition of osteoclasts is proposed to be the main treatment for osteolytic disorders. Diosmetin (DIO) is a natural flavonoid with properties of antioxidant, anti-infection, and antishock. The effect of DIO on osteoclast differentiation is poorly understood. In this study project, we found that DIO could inhibit osteoclastic formation induced by receptor activator of nuclear factor kappa-B ligand (RANKL) in a dose-dependent manner. The expression of the osteoclast differentiation marker genes, cathepsin K, nuclear factor of activated T-cells 1 (NFATc1), Acp5, Ctr, Atp6v0d2, and Mmp9 were also decreased by the treatment of DIO. In addition, DIO attenuated the formation of actin ring and the ability of bone resorption. Further, the western blotting showed that DIO inhibits the phosphorylation of the mitogen-activated protein kinases signaling pathway induced by RANKL, accompanied by the downregulation of NFATc1 and c-Fos expression. We also found that DIO could reduce the accumulation of reactive oxygen species (ROS) induced by RANKL. In vivo, the study revealed that DIO can significantly reduce LPS-induced osteolysis in mice. Collectively, our study shows that DIO can inhibit osteoclast formation and activation, and could serve as a potential therapeutic drug for osteolytic bone diseases.
Insights
Diosmetin (DIO) effectively inhibits osteoclast formation and bone resorption, offering a potential treatment for osteolytic bone diseases. This natural flavonoid reduces key markers and pathways involved in bone breakdown.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteolytic bone diseases involve excessive osteoclast activity and bone resorption, posing significant clinical challenges.
- Current treatments focus on inhibiting osteoclasts, but novel therapeutic agents are needed.
- Diosmetin (DIO), a natural flavonoid, possesses antioxidant and anti-inflammatory properties, but its effect on osteoclast differentiation is largely unknown.
Purpose of the Study:
- To investigate the effect of Diosmetin (DIO) on osteoclast differentiation and bone resorption.
- To elucidate the molecular mechanisms underlying DIO's action on osteoclasts.
- To evaluate the therapeutic potential of DIO in an in vivo model of osteolysis.
Main Methods:
- Osteoclast differentiation was induced by receptor activator of nuclear factor kappa-B ligand (RANKL) in vitro.
- Gene expression of osteoclast markers (cathepsin K, NFATc1, Acp5, Ctr, Atp6v0d2, Mmp9) was analyzed.
- Actin ring formation and bone resorption assays were performed.
- Western blotting assessed signaling pathways (MAPK) and transcription factors (NFATc1, c-Fos).
- Reactive oxygen species (ROS) levels were measured.
- An in vivo mouse model of lipopolysaccharide (LPS)-induced osteolysis was used.
Main Results:
- DIO dose-dependently inhibited RANKL-induced osteoclast formation.
- DIO decreased the expression of key osteoclast differentiation markers.
- DIO attenuated actin ring formation and bone resorption.
- DIO inhibited the RANKL-induced MAPK signaling pathway and downregulated NFATc1 and c-Fos.
- DIO reduced RANKL-induced ROS accumulation.
- DIO significantly ameliorated LPS-induced osteolysis in mice.
Conclusions:
- Diosmetin (DIO) effectively inhibits osteoclast formation and activation.
- DIO acts by suppressing the MAPK signaling pathway and reducing ROS production.
- DIO demonstrates therapeutic potential as a novel agent for treating osteolytic bone diseases.
Related Concept Videos
Feedback Inhibition
Osteoclasts in Bone Remodeling
Cancer Prevention
Some...
Formation of Species
Enzyme Inhibition
Prevention of Further Absorption of Poison

